Efficacy and safety of sarolaner against generalized demodicosis in dogs in European countries: a non‐inferiority study

Becskei, Csilla; Cuppens, Otto; Mahabir, Sean P.

doi:10.1111/vde.12526

Cited by 26 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no treatment‐related adverse events observed. A subsequent noninferiority study compared the same two products in 81 client‐owned dogs . Parasitological cure in dogs treated with sarolaner was achieved in 93% after three months and 100% after five months, confirming the efficacy of sarolaner against canine generalized demodicosis.…”

Section: Treatmentmentioning

confidence: 84%

Diagnosis and treatment of demodicosis in dogs and cats

Mueller¹,

Rosenkrantz²,

Bensignor³

et al. 2020

Veterinary Dermatology

View full text Add to dashboard Cite

Background Demodicosis is a common disease in small animal veterinary practice worldwide with a variety of diagnostic and therapeutic options. Objectives To provide consensus recommendations on the diagnosis, prevention and treatment of demodicosis in dogs and cats. Methods and materials The authors served as a Guideline Panel (GP) and reviewed the literature available before December 2018. The GP prepared a detailed literature review and made recommendations on selected topics. A draft of the document was presented at the North American Veterinary Dermatology Forum in Maui, HI, USA (May 2018) and at the European Veterinary Dermatology Congress in Dubrovnik, Croatia (September 2018) and was made available via the World Wide Web to the member organizations of the World Association for Veterinary Dermatology for a period of three months. Comments were solicited and responses were incorporated into the final document. Conclusions In young dogs with generalized demodicosis, genetic and immunological factors seem to play a role in the pathogenesis and affected dogs should not be bred. In old dogs and cats, underlying immunosuppressive conditions contributing to demodicosis should be explored. Deep skin scrapings are the diagnostic gold standard for demodicosis, but trichograms and tape squeeze preparations may also be useful under certain circumstances. Amitraz, macrocyclic lactones and more recently isoxazolines have all demonstrated good efficacy in the treatment of canine demodicosis. Therapeutic selection should be guided by local drug legislation, drug availability and individual case parameters. Evidence for successful treatment of feline demodicosis is strongest for lime sulfur dips and amitraz baths.

show abstract

Section: Treatmentmentioning

confidence: 84%

Diagnosis and treatment of demodicosis in dogs and cats

Mueller¹,

Rosenkrantz²,

Bensignor³

et al. 2020

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Across Albania (60), Germany (3), Spain (7), Portugal (14), and Poland (50), 134 dogs were enrolled, ranging in age in the oral uralaner group from 10 weeks to 13 years (mean 3.1; standard deviation ± 2.9 years), in the spoton uralaner group from 4 months to 12 years (3.5 ± 3.2 years), and in the topical imidacloprid-moxidectin group from 11 weeks to 9 years (2.9 ± 2.9 years). A broad range of breed categories was represented, with approximately 50% of dogs mixed breed, 22% were companion-toy dogs, and approximately 9% were terriers.…”

Section: Resultsmentioning

confidence: 99%

“…Where necessary (e.g. long or medium-haired dogs), hair was removed at the area to be scraped, and the skin was rmly squeezed prior to and during scraping to eject mites from hair follicles [2,14,15]. Scrapings were made in the direction of hair growth with a blade or spatula, covered with mineral oil, until capillary oozing was observed.…”

Section: Assessments Of Demodicosismentioning

confidence: 99%

See 1 more Smart Citation

A European Field Assessment of the efficacy of fluralaner (Bravecto®) chewable and spot-on formulations for treatment of dogs with generalized demodicosis

Petersen

Chiummo

Zschiesche

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : Recent reports indicate that the isoxazoline compounds have the potential to provide safe and effective treatment of canine generalized demodicosis, a condition that has been traditionally difficult to cure. Controlled field studies are needed to confirm this potential. A study was therefore initiated to investigate the efficacy of a single oral or spot-on treatment with fluralaner, an isoxazoline, compared with multiple topical treatments with imidacloprid-moxidectin, in dogs naturally affected by generalized demodicosis. Methods : Veterinary clinics in 5 European countries enrolled 134 dogs diagnosed with generalized demodicosis. Dogs were randomized to treatment with either fluralaner chewables, fluralaner spot-on, or topical imidacloprid-moxidectin in a 2:2:1 ratio. Both fluralaner formulations were administered once, at the approved dose rate, on day 0. Imidacloprid-moxidectin was administered per label on day 0, and every 4 weeks, more frequently if necessary. At each visit (days 0, 28, 56, 84), dogs were monitored for demodectic mites, using deep skin scrapings, and observed for health and for severity of skin lesions. Treatment was considered efficacious if more than 90% of the dogs were free of live mites at both days 56 and 84. Results : Of 124 dogs completing the study, 57 were diagnosed with juvenile-onset demodicosis and 67 with the adult-onset form. A single treatment with oral or spot-on fluralaner was efficacious, each eliminating mites from at least 98.0% of treated dogs on days 56 and 84. Against juvenile-onset demodicosis, efficacy of the oral and spot-on formulations was 96.0% and 100%, respectively, and against adult-onset demodicosis 100% and 96.7%. Multiple administrations of imidacloprid-moxidectin were not efficacious, eliminating mites from 87.5% of dogs (92.0% with juvenile-onset demodicosis cured; 81.8% with adult-onset demodicosis). All groups showed a marked reduction in skin lesions by day 28, with continuing clinical improvement at each subsequent visit through day 84. There were no treatment-related adverse events. Conclusion : A single administration of fluralaner chewables or fluralaner spot-on is highly effective against juvenile-onset and adult-onset forms of generalized canine demodicosis. Topically applied imidacloprid-moxidectin at weekly to monthly intervals over the 84-day study did not achieve the proportion of mite-free dogs required to demonstrate efficacy.

show abstract

“…All five studies were sponsored by the pharmaceutical companies that make the isoxazoline preparations and nearly all authors were employees of these companies. This may bias study design and reporting of results as demonstrated in the study by Becskei et al (2018) where sarolaner is claimed to be as good as, if not better than moxidectin/imidacloprid, but the study was only designed to prove non-inferiority. In each paper the dosing frequency of moxidectin/imidacloprid varied making them harder to compare.…”

Section: Appraisal Application and Reflectionmentioning

confidence: 99%

Choosing Treatment for Dogs With Generalised Demodicosis – Isoxazolines or Imidacloprid and Moxidectin?

Long¹

2019

View full text Add to dashboard Cite

PICO questionIn dogs with generalised demodicosis, are isoxazolines as effective as a combined formulation of imidacloprid and moxidectin at reducing mite count and the severity of associated clinical signs?Clinical bottom lineFive single-blinded, randomised, positive control trials, most under laboratory conditions, directly compared the use of isoxazolines against moxidectin/imidacloprid to treat canine generalised demodicosis. All of them showed comparable efficacy of isoxazolines. Three different isoxazolines were studied with two routes of administration (oral and topical) and four different dosing frequencies of moxidectin/imidacloprid. This made the papers more challenging to compare however, the evidence provided is sufficient to support their use. All of these trials were sponsored by the manufacturers of their respective isoxazoline products which may bias the study design and reporting of results. It is worth noting that sarolaner (Simparica™, Zoetis UK) was licensed in the UK for the treatment of canine demodicosis in January 2018 and that in the UK the Cascade should be followed when prescribing treatments. The licensed use of isoxazolines in other countries is beyond the scope of this article and the reader is urged to check local regulatory body advice before prescribing the below medications. <img src="https://www.veterinaryevidence.org/rcvskmod/icons/oa-icon.jpg" alt="Open Access" /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/pr-icon.jpg" alt="Peer Reviewed" />

show abstract

Efficacy and safety of sarolaner against generalized demodicosis in dogs in European countries: a non‐inferiority study

Abstract: Monthly oral administration of sarolaner was safe and highly effective in the treatment of generalized demodicosis in dogs.

Cited by 26 publications

References 15 publications

Diagnosis and treatment of demodicosis in dogs and cats

Diagnosis and treatment of demodicosis in dogs and cats

A European Field Assessment of the efficacy of fluralaner (Bravecto®) chewable and spot-on formulations for treatment of dogs with generalized demodicosis

Choosing Treatment for Dogs With Generalised Demodicosis – Isoxazolines or Imidacloprid and Moxidectin?

Contact Info

Product

Resources

About